X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs NATCO PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA NATCO PHARMA ASTRAZENECA PHARMA/
NATCO PHARMA
 
P/E (TTM) x 123.4 19.1 647.6% View Chart
P/BV x 17.6 18.2 96.3% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
NATCO PHARMA
Mar-14
ASTRAZENECA PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,285877 146.5%   
Low Rs634424 149.7%   
Sales per share (Unadj.) Rs189.6223.4 84.9%  
Earnings per share (Unadj.) Rs-0.231.1 -0.7%  
Cash flow per share (Unadj.) Rs3.840.3 9.5%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs68.6219.5 31.3%  
Shares outstanding (eoy) m25.0033.07 75.6%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x5.12.9 173.9%   
Avg P/E ratio x-4,712.720.9 -22,516.1%  
P/CF ratio (eoy) x249.616.1 1,545.8%  
Price / Book Value ratio x14.03.0 471.9%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m23,98821,504 111.6%   
No. of employees `0001.6NA-   
Total wages/salary Rs m1,6051,128 142.3%   
Avg. sales/employee Rs Th3,040.2NM-  
Avg. wages/employee Rs Th1,029.2NM-  
Avg. net profit/employee Rs Th-3.3NM-  
INCOME DATA
Net Sales Rs m4,7407,389 64.1%  
Other income Rs m92167 55.1%   
Total revenues Rs m4,8327,556 63.9%   
Gross profit Rs m-1301,793 -7.2%  
Depreciation Rs m101304 33.2%   
Interest Rs m0366 0.0%   
Profit before tax Rs m-1391,290 -10.8%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5309 1.6%   
Profit after tax Rs m-51,027 -0.5%  
Gross profit margin %-2.724.3 -11.3%  
Effective tax rate %-3.723.9 -15.3%   
Net profit margin %-0.113.9 -0.8%  
BALANCE SHEET DATA
Current assets Rs m2,7263,681 74.1%   
Current liabilities Rs m2,4353,123 78.0%   
Net working cap to sales %6.17.6 81.3%  
Current ratio x1.11.2 95.0%  
Inventory Days Days7489 82.4%  
Debtors Days Days4159 69.5%  
Net fixed assets Rs m1,0357,685 13.5%   
Share capital Rs m50331 15.1%   
"Free" reserves Rs m9426,670 14.1%   
Net worth Rs m1,7167,259 23.6%   
Long term debt Rs m0955 0.0%   
Total assets Rs m4,15611,957 34.8%  
Interest coverage xNM4.5-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.10.6 184.6%   
Return on assets %-0.111.7 -1.1%  
Return on equity %-0.314.2 -2.1%  
Return on capital %020.7 0.0%  
Exports to sales %5.739.4 14.5%   
Imports to sales %6.55.7 113.4%   
Exports (fob) Rs m2702,908 9.3%   
Imports (cif) Rs m306421 72.7%   
Fx inflow Rs m3753,445 10.9%   
Fx outflow Rs m470703 66.9%   
Net fx Rs m-962,743 -3.5%   
CASH FLOW
From Operations Rs m-81,440 -0.6%  
From Investments Rs m-146-1,089 13.4%  
From Financial Activity Rs m862-353 -244.5%  
Net Cashflow Rs m709-1 -47,550.3%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 1.5 5,102.0%  
Indian inst/Mut Fund % 0.3 7.8 3.8%  
FIIs % 15.7 16.6 94.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 26.0 35.0%  
Shareholders   12,856 25,395 50.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   MERCK LTD  STERLING BIOTECH  TORRENT PHARMA  SUVEN LIFE  CIPLA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Energy and IT Stocks Witness Buying(12:30 pm)

Stock markets in India are presently trading on a positive note. Sectoral indices are trading on a positive note with stocks in the energy sector and IT sector witnessing maximum buying interest.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


May 25, 2018 02:15 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS